EA201792608A3 - Применение белков p3 бактериофага в качестве агентов, связывающих амилоид - Google Patents
Применение белков p3 бактериофага в качестве агентов, связывающих амилоидInfo
- Publication number
- EA201792608A3 EA201792608A3 EA201792608A EA201792608A EA201792608A3 EA 201792608 A3 EA201792608 A3 EA 201792608A3 EA 201792608 A EA201792608 A EA 201792608A EA 201792608 A EA201792608 A EA 201792608A EA 201792608 A3 EA201792608 A3 EA 201792608A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- amyloid
- bacteriophag
- agylines
- protein
- application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
Abstract
В настоящем изобретении предложены агенты и фармацевтические композиции для уменьшения образования амилоида и/или усиления дезагрегации амилоидных белков. Композиции также можно применять для детектирования амилоида.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564602P | 2011-11-29 | 2011-11-29 | |
US201261708709P | 2012-10-02 | 2012-10-02 | |
US201261730316P | 2012-11-27 | 2012-11-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201792608A2 EA201792608A2 (ru) | 2018-04-30 |
EA201792608A3 true EA201792608A3 (ru) | 2018-08-31 |
Family
ID=47326403
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201491063A EA029602B1 (ru) | 2011-11-29 | 2012-11-28 | Применение белков р3 бактериофага в качестве агентов, связывающих амилоид |
EA201792608A EA201792608A3 (ru) | 2011-11-29 | 2012-11-28 | Применение белков p3 бактериофага в качестве агентов, связывающих амилоид |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201491063A EA029602B1 (ru) | 2011-11-29 | 2012-11-28 | Применение белков р3 бактериофага в качестве агентов, связывающих амилоид |
Country Status (16)
Country | Link |
---|---|
US (3) | US9493515B2 (ru) |
EP (1) | EP2785364B1 (ru) |
JP (2) | JP6220344B2 (ru) |
KR (1) | KR20140100543A (ru) |
CN (2) | CN114748605A (ru) |
AU (1) | AU2012346056B2 (ru) |
BR (1) | BR112014013086A2 (ru) |
CA (1) | CA2857539C (ru) |
EA (2) | EA029602B1 (ru) |
IL (1) | IL232867B (ru) |
IN (1) | IN2014CN04587A (ru) |
MX (1) | MX362175B (ru) |
PH (1) | PH12014501200A1 (ru) |
SG (2) | SG11201402425TA (ru) |
WO (1) | WO2013082114A1 (ru) |
ZA (1) | ZA201403863B (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014013086A2 (pt) | 2011-11-29 | 2020-10-27 | Neurophage Pharmaceuticals, Inc. | Composições para tratamento de doença associada com proteína amiloide agregada epara detectar ou gerar imagem de amiloide agregada e uso das referidas composições |
PL2906235T3 (pl) | 2012-10-02 | 2017-12-29 | Proclara Biosciences, Inc. | Wykorzystanie p3 białek fuzyjnych bakteriofaga jako środków wiążących amyloid |
US9988444B2 (en) * | 2013-05-28 | 2018-06-05 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
JP6730988B2 (ja) | 2014-12-03 | 2020-07-29 | プロクララ バイオサイエンシーズ, インコーポレイテッド | グリコシル化シグナルを欠く改変バクテリオファージg3pアミノ酸配列を含むポリペプチド |
US11066460B2 (en) * | 2015-11-25 | 2021-07-20 | Eli Lilly And Company | Phage display vectors and methods of use |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
RU2740573C1 (ru) * | 2017-07-14 | 2021-01-15 | Гсе Холдинг Аб | Электронный измеритель для контроля баллона со сжатым газом, и соответствующие способы |
BR112020025111A2 (pt) | 2018-06-15 | 2021-04-06 | Proclara Biosciences, Inc. | Motivo de interação amiloide geral (gaim) |
WO2024119183A1 (en) | 2022-12-02 | 2024-06-06 | Alzheon, Inc. | Methods for treating neurodegenerative disorders with tramiprosate |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
DE59010933D1 (de) | 1989-09-12 | 2003-05-08 | Hoffmann La Roche | TFN-bindende Proteine |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
SG47099A1 (en) | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
DE69334070T2 (de) | 1992-05-26 | 2007-01-04 | Immunex Corp., Thousand Oaks | Neue zytokine die cd30 binden |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
KR20040074587A (ko) | 2001-02-19 | 2004-08-25 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 인공 단백질 |
EP1366074B1 (en) | 2001-03-08 | 2006-09-13 | MERCK PATENT GmbH | Modified granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
US7385123B2 (en) | 2002-08-20 | 2008-06-10 | Sungene Gmbh & Co. Kgaa | Process for preparing ketocarotenoids in genetically modified organisms |
DE10238846A1 (de) * | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Aktive Fusionsproteine und Verfahren zu ihrer Herstellung |
US7867487B2 (en) * | 2005-02-01 | 2011-01-11 | Ramot At Tel-Aviv University Ltd. | Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia |
EP2808032B1 (en) * | 2005-12-12 | 2018-08-01 | AC Immune S.A. | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
US20090304726A1 (en) | 2006-02-15 | 2009-12-10 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
WO2007095616A2 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
WO2007109733A2 (en) * | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
US20090105090A1 (en) * | 2006-04-06 | 2009-04-23 | Fumiaki Uchiyama | Phage Display By Novel Filamentous Bacteriophage |
EP2054515B1 (en) | 2006-07-21 | 2012-01-11 | Ramot at Tel-Aviv University Ltd. | Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates |
SG175596A1 (en) | 2006-10-11 | 2011-11-28 | Antitope Ltd | T cell epitope databases |
EP2303315A1 (en) | 2008-05-22 | 2011-04-06 | Ramot at Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
WO2010011947A2 (en) * | 2008-07-25 | 2010-01-28 | Abbott Laboratories | AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES |
EP2356231A2 (en) * | 2008-09-26 | 2011-08-17 | Wyeth LLC | Compatible display vector systems |
KR20110091778A (ko) | 2008-11-24 | 2011-08-12 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 사상 박테리오파지를 이용하는 파킨슨병의 치료방법 |
WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
KR20140051840A (ko) | 2011-03-11 | 2014-05-02 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 신경변성 타우오패씨를 치료하는 방법 |
US8856364B2 (en) | 2011-03-11 | 2014-10-07 | Google Inc. | Conducting opportunistic network updates on a mobile device |
BR112014013086A2 (pt) | 2011-11-29 | 2020-10-27 | Neurophage Pharmaceuticals, Inc. | Composições para tratamento de doença associada com proteína amiloide agregada epara detectar ou gerar imagem de amiloide agregada e uso das referidas composições |
PL2906235T3 (pl) | 2012-10-02 | 2017-12-29 | Proclara Biosciences, Inc. | Wykorzystanie p3 białek fuzyjnych bakteriofaga jako środków wiążących amyloid |
US9988444B2 (en) | 2013-05-28 | 2018-06-05 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
JP6730988B2 (ja) | 2014-12-03 | 2020-07-29 | プロクララ バイオサイエンシーズ, インコーポレイテッド | グリコシル化シグナルを欠く改変バクテリオファージg3pアミノ酸配列を含むポリペプチド |
-
2012
- 2012-11-28 BR BR112014013086-8A patent/BR112014013086A2/pt not_active Application Discontinuation
- 2012-11-28 AU AU2012346056A patent/AU2012346056B2/en active Active
- 2012-11-28 EP EP12799008.3A patent/EP2785364B1/en active Active
- 2012-11-28 SG SG11201402425TA patent/SG11201402425TA/en unknown
- 2012-11-28 WO PCT/US2012/066793 patent/WO2013082114A1/en active Application Filing
- 2012-11-28 MX MX2014006337A patent/MX362175B/es active IP Right Grant
- 2012-11-28 EA EA201491063A patent/EA029602B1/ru unknown
- 2012-11-28 CN CN202210423575.9A patent/CN114748605A/zh active Pending
- 2012-11-28 CN CN201280066659.6A patent/CN104093414A/zh active Pending
- 2012-11-28 SG SG10201709849TA patent/SG10201709849TA/en unknown
- 2012-11-28 JP JP2014543617A patent/JP6220344B2/ja active Active
- 2012-11-28 EA EA201792608A patent/EA201792608A3/ru unknown
- 2012-11-28 KR KR1020147017548A patent/KR20140100543A/ko not_active Application Discontinuation
- 2012-11-28 US US14/361,157 patent/US9493515B2/en active Active
- 2012-11-28 CA CA2857539A patent/CA2857539C/en active Active
-
2014
- 2014-05-27 ZA ZA2014/03863A patent/ZA201403863B/en unknown
- 2014-05-28 PH PH12014501200A patent/PH12014501200A1/en unknown
- 2014-05-29 IL IL232867A patent/IL232867B/en active IP Right Grant
- 2014-06-18 IN IN4587CHN2014 patent/IN2014CN04587A/en unknown
-
2015
- 2015-07-13 US US14/797,724 patent/US9493516B2/en active Active
-
2016
- 2016-10-07 US US15/288,237 patent/US10151762B2/en active Active
-
2017
- 2017-04-04 JP JP2017074284A patent/JP6440765B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792608A2 (ru) | Применение белков p3 бактериофага в качестве агентов, связывающих амилоид | |
CY1123958T1 (el) | Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης | |
EA201491644A1 (ru) | Фармацевтические композиции | |
EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
EA201171494A1 (ru) | Миметики белка smac | |
EA202193044A2 (ru) | Способы лечения таупатии | |
EA201690667A1 (ru) | Композиции, содержащие антитело к pdl1 | |
EA201892509A1 (ru) | Антитела к гемагглютинину и способы применения | |
EA201590690A1 (ru) | Применение р3 из белков слияния бактериофага в качестве амилоидсвязывающих веществ | |
EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
EA201590931A1 (ru) | Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
MX2019007921A (es) | Nuevos agentes de union a ha. | |
UA112416C2 (uk) | Антитіло до fap і способи його застосування | |
EA201391540A1 (ru) | Агонисты fgfr1 и способы их применения | |
EA201992133A1 (ru) | Производные пиперидино-пиримидина для лечения вирусных инфекций | |
EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
EA201170396A1 (ru) | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции | |
EA201270722A1 (ru) | Формы рифаксимина и их применение | |
EA201791717A1 (ru) | Стабильные водные составы адалимумаба | |
EA201492216A1 (ru) | Ингибиторы бромодомена и их применение | |
UY34343A (es) | Proteinas de unión al antígeno cd27l | |
EA201791733A1 (ru) | Производные 9h-пирролодипиридина | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения |